These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37152423)

  • 1. Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors - can we RECIST? Focus on colorectal cancer.
    Spindler KG; Jakobsen A
    Ther Adv Med Oncol; 2023; 15():17588359231171580. PubMed ID: 37152423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology.
    Jakobsen AKM; Spindler KG
    Eur J Cancer; 2023 Feb; 180():180-183. PubMed ID: 36610263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
    Tie J; Kinde I; Wang Y; Wong HL; Roebert J; Christie M; Tacey M; Wong R; Singh M; Karapetis CS; Desai J; Tran B; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2015 Aug; 26(8):1715-22. PubMed ID: 25851626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer.
    Gong J; Aguirre F; Hazelett D; Alvarez R; Zhou L; Hendifar A; Osipov A; Zaghiyan K; Cho M; Gangi A; Hitchins M
    Mol Clin Oncol; 2022 May; 16(5):100. PubMed ID: 35463213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
    Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
    Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
    [No Abstract]   [Full Text] [Related]  

  • 6. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).
    Chakrabarti S; Kasi AK; Parikh AR; Mahipal A
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
    Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
    Naqvi MF; Vo HH; Vining D; Tsimberidou AM
    Ther Adv Med Oncol; 2021; 13():17588359211001538. PubMed ID: 33995588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer.
    Reece M; Saluja H; Hollington P; Karapetis CS; Vatandoust S; Young GP; Symonds EL
    Front Genet; 2019; 10():1118. PubMed ID: 31824558
    [No Abstract]   [Full Text] [Related]  

  • 11. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics.
    Lv J; Wu C; Li J; Chen F; He S; He Q; Zhou G; Ma J; Sun Y; Wei D; Lin L
    BMC Med; 2022 Aug; 20(1):268. PubMed ID: 35996151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
    Vidal J; Muinelo L; Dalmases A; Jones F; Edelstein D; Iglesias M; Orrillo M; Abalo A; Rodríguez C; Brozos E; Vidal Y; Candamio S; Vázquez F; Ruiz J; Guix M; Visa L; Sikri V; Albanell J; Bellosillo B; López R; Montagut C
    Ann Oncol; 2017 Jun; 28(6):1325-1332. PubMed ID: 28419195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer.
    Gong J; Hendifar A; Gangi A; Zaghiyan K; Atkins K; Nasseri Y; Murrell Z; Figueiredo JC; Salvy S; Haile R; Hitchins M
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy.
    Lee S; Park YS; Chang WJ; Choi JY; Lim A; Kim B; Lee SB; Lee JW; Kim SH; Kim J; Kwak JM; Yoon KC; Lee SH; Kim YH
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
    Bidard FC; Kiavue N; Ychou M; Cabel L; Stern MH; Madic J; Saliou A; Rampanou A; Decraene C; Bouché O; Rivoire M; Ghiringhelli F; Francois E; Guimbaud R; Mineur L; Khemissa-Akouz F; Mazard T; Moussata D; Proudhon C; Pierga JY; Stanbury T; Thézenas S; Mariani P
    Cells; 2019 May; 8(6):. PubMed ID: 31142037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer.
    Lin CY; Shen MY; Chen WT; Yang CA
    J Pers Med; 2023 Jun; 13(7):. PubMed ID: 37511664
    [No Abstract]   [Full Text] [Related]  

  • 18. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
    Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
    Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
    Benavides M; Alcaide-Garcia J; Torres E; Gil-Calle S; Sevilla I; Wolman R; Durán G; Álvarez M; Reyna-Fortes C; Ales I; Pereda T; Robles M; Kushnir M; Odegaard J; Faull I; Alba E
    ESMO Open; 2022 Jun; 7(3):100481. PubMed ID: 35525184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.